Portal de investigación
ENSAYO CLÍNICO FASE IB/II DE NIVOLUMAB EN MONOTERAPIA Y NIVOLUMAB EN COMBINACIÓN CON IPILIMUMAB EN PACIENTES PEDIÁTRICOS CON NEOPLASIAS MALIGNAS PRIMARIAS DEL SNC DE ALTO GRADO.
Datos básicos
- Protocolo:
- CA209-908
- EUDRACT:
- 2016-004441-82
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2017
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors
Tadeo, I; (...); Noguera, R
Article. 10.1467/HH-11-947. 2018
A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors.
Cerda Alberich, Leonor; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers12123858. 2020
A NATIONAL PEDIATRIC NEURO-ONCOLOGY TUMOR BOARD INITIATIVE IN SPAIN: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE UTILIZING THIS RESOURCE
Illade, Laura; (...); Lassaletta, Alvaro
Article. 2022
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma
Van Hal, Gertjan; (...); Lewin, Jeremy Howard
Meeting Abstract. 2023
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); Vagace Valero, Jose Manuel
Article. 10.1016/j.anpede.2023.01.003. 2023
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); SEHOP
Article. 10.1016/j.anpedi.2022.09.012. 2023
Alectinib in pediatric patients with solid or CNS tumors harboring ALK-fusions: Emerging pharmacokinetic data from the iMATRIX alectinib phase I/II open-label, multi-center study
Doz, Francois; (...); Gajjar, Amar J.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.3098. 2024
ASSESSMENT OF A NOVEL READY-TO-USE TEMOZOLOMIDE ORAL SUSPENSION IN CHILDREN WITH SOLID TUMORS: RESULTS OF TEMOKIDS, A POPULATION PHARMACOKINETIC, ACCEPTABILITY AND SAFETY PHASE-1 STUDY
Abbou, Samuel; (...); Metayer, Lucy
Meeting Abstract. 2023
Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma I-131-mIBG treatment
Chimeno, JM; (...); Montoro, A
Article. 10.1080/09553002.2019.1549755. 2018
Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study.
van den Oever, Selina R; (...); Pluijm, Saskia M F
Article. 10.1007/s11764-023-01335-y. 2023
Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.
de Beijer IAE; (...); Pluijm SMF
Article. 10.1007/s11764-023-01498-8. 2023
Bridges to pediatric stem cell transplant: a new lane through
Torres Guerola, Barbara, Carreno Sanchez, Sandra, Fernandez Navarro, Jose Maria
Meeting Abstract. 2018
Cadmium (Cd) and Lead (Pb) topsoil levels and incidence of childhood leukemias
Asenjo S; (...); Ramis R
Article. 10.1007/s10653-021-01030-w. 2021
Can We Identify Chemotherapy-Related Toxicity in Children with Cancer Through Automatized Integration of Healthcare Information Systems?
Berlanga, P; (...); Canete, A
Meeting Abstract. 2017
Cáncer en los primeros 18 meses de vida.
Urtasun Erburu A, Herrero Cervera MJ, Cañete Nieto A
Article. 10.1016/j.anpedi.2020.02.015. 2020
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbidities.
Velasco Puyó P; (...); Astigarraga I
Article. 10.1002/pbc.31120. 2024
Casuística de tumor miofibroblástico inflamatorio en centro terciario.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpedi.2020.12.007. 2021
Casuistics of inflammatory myofibroblastic tumor in a tertiary center.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpede.2020.12.016. 2021
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
Berlanga, P; (...); Ladenstein, R
Article. 10.1016/j.ejca.2020.10.020. 2021
Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients
Espallardo, I. Torres; (...); Prado-Wohlwend, S.
Meeting Abstract. 2023
Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
J Ribelles A; (...); Castel V
Article. 10.1038/s41598-019-50327-5. 2019
Cmo tratamos el hemangioendotelioma kaposiforme?
Huerta-Calpe S; (...); Pérez-Tarazona S
Article. 10.1016/j.anpedi.2018.09.002. 2019
COMBINED RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR OUTCOME EVALUATION IN NEWLY DIAGNOSED NON-BRAINSTEM PEDIATRIC HIGH-GRADE GLIOMA FROM THE RANDOMIZED, MULTICENTER HERBY PHASE II TRIAL
Jaspan, T; (...); Grill, J
Meeting Abstract. 2018
Comparative Multicentric Evaluation of Inter-Observer Variability in Manual and Automatic Segmentation of Neuroblastic Tumors in Magnetic Resonance Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers14153648. 2022
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Campbell, K; (...); DuBois, SG
Article. 10.1002/pbc.27819. 2019
Congenital Critical Heart Defect Screening in a Health Area of the Community of Valencia (Spain): A Prospective Observational Study
Cubells, E; (...); Vento, M
Article. 10.3390/ijns4010003. 2018
Consensus SEO-SEFH of recommendations for use and compounding of ophthalmic preparations.
Fuentes-Irigoyen, R; (...); Yañez Martínez JR
Article. 10.7399/fh.10943. 2018
Correction: Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.
de Beijer IAE; (...); Pluijm SMF
Correction. 10.1007/s11764-024-01547-w. 2024
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Gargallo, P.; (...); Moreno, L.
Article. 10.1007/s12094-021-02759-7. 2022
Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Rubio-San-Simon, A.; (...); Bautista, F.
Article. 10.1007/s12094-020-02399-3. 2021
Childhood and Adolescent Central Nervous System Tumours in Spain: Incidence and Survival over 20 Years: A Historical Baseline for Current Assessment.
Chirlaque MD; (...); The Spanish Childhood Cancer Epidemiology Working Group
Article. 10.3390/cancers15245889. 2023
Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition
Sanmartin, E; (...); Font de Mora J
Article. 10.1158/1078-0432.CCR-17-0593. 2017
Delving into the clinical impact of NETs in pediatric cancer.
Benavent N; (...); Medina P
Article. 10.1038/s41390-024-03437-4. 2024
Development of Hepatoblastoma organoids as a patient-derived ex-vivo system
Zanatto, Laura; (...); Sancho-Bru, Pau
Meeting Abstract. 2022
Development of the ECLIM-SEHOP Clinical Trial Platform: Implementing International Academic Clinical Trials for Childhood Cancer and Blood Disorders in Spain
Fernandez-Teijeiro, A; (...); Moreno, L
Meeting Abstract. 2020
Distribution of segmental chromosomal alterations in neuroblastoma.
Juan Ribelles A; (...); Castel V
Article. 10.1007/s12094-020-02497-2. 2020
Early clinical trials in paediatric oncology in Spain: a nationwide perspective
Bautista, F; (...); Sociedad Española de Hematología y Oncología Pediátrica (SEHOP) and the New Drug
Article. 10.1016/j.anpedi.2016.07.007. 2017
ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain.
Bautista, F; (...); Sociedad Española de Hematología y Oncología Pediátrica (SEHOP)
Article. 10.1007/s12094-019-02221-9. 2019
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A; (...); Fernández-Teijeiro A
Article. 10.1007/s12094-024-03445-0. 2024
Endocrinological late effects of oncologic treatment on survivors of medulloblastoma
Santos, ADH; (...); Nieto, AC
Article. 10.32641/rchped.v90i6.994. 2019
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications
Carrillo-Reixach, J; (...); Armengol, C
Article. 10.1016/j.jhep.2020.03.025. 2020
Epigenetics and Oxidative Stress in Aging
Guillaumet-Adkins, A; (...); Sandoval, J
Review. 10.1155/2017/9175806. 2017
Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
Trinidad, Eva Maria; (...); de Mora, Jaime Font
Article. 10.3389/fonc.2023.1037342. 2023
EVALUATION OF THE IMPLEMENTATION OF THE RANO CRITERIA IN THE HERBY TRIAL OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Rodriguez, D; (...); Jaspan, T
Meeting Abstract. 2018
Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis
Corrias, MV; (...); Burchill, SA
Article. 10.1002/pbc.27052. 2018
Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study.
Morini M; (...); Varesio L
Article. 10.3390/cancers11101476. 2019
Free flaps as a first option for reconstruction of shoulder girdle high recurrence risk tumors.
Pérez-García A; (...); Baixauli F
Letter. 10.1002/jso.26064. 2020
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Gargallo P; (...); Cañete A
Article. 10.3390/cancers13215339. 2021
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Gargallo, Pablo; (...); Font de Mora, Jaime
Article. 10.1038/s41431-022-01105-x. 2022
Global Retinoblastoma Presentation and Analysis by National Income Level.
Global Retinoblastoma Study Group; (...); Bowman R
Article. 10.1001/jamaoncol.2019.6716. 2020
High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
Monferrer, E; (...); Noguera, R
Article. 10.1186/s12885-018-5219-3. 2019
HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE
Ladenstein, Ruth; (...); Canete, Adela
Meeting Abstract. 2023
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial
Ladenstein, Ruth Lydia; (...); Canete, Adela
Meeting Abstract. 2023
High-risk neuroblastoma: where do we go?
Editorial Material. 10.1016/j.annonc.2019.12.003. 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.
Rubio-San-Simón A; (...); Bautista F
Article. 10.1016/j.ejca.2020.09.024. 2020
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers15051622. 2023
Influence of Sex on Gestational Complications, Fetal-to-Neonatal Transition, and Postnatal Adaptation
Lorente-Pozo, Sheila; (...); Vento, Maximo
Review. 10.3389/fped.2018.00063. 2018
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic
Faura, A; (...); Dapena, JL
Letter. 10.1002/pbc.28557. 2020
International benchmarking of childhood cancer survival by tumour stage: First results of the BENCHISTA project
Pritchard-Jones, K.; (...); Gatta, G.
Meeting Abstract. 2024
International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study.
Botta, Laura; (...); Pritchard-Jones, Kathy
Article. 10.1016/S2352-4642(24)00302-X. 2025
Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Coronado, Esther; (...); Font de Mora, Jaime
Article. 10.1002/1878-0261.12868. 2021
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.
de Beijer, Ismay A E; (...); Chronaki, Catherine
Article. 10.2196/49910. 2024
Lateral-type posterior fossa ependymomas in pediatric population
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucir.2023.10.002. 2024
Lateral-type posterior fossa ependymomas in pediatric population.
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucie.2023.10.001. 2024
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050) : a multicentre, open-label, multicohort, phase 1/2 study
Gaspar, N; (...); Campbell-Hewson, Q
Article. 10.1016/S1470-2045(21)00387-9. 2021
Li-Fraumeni syndrome heterogeneity.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-019-02236-2. 2020
Li-Fraumeni: Will the detection in families increase the survival of its members?
Gargallo, P; (...); Canete, A
Letter. 10.1016/j.anpedi.2018.03.009. 2019
Liquid Biopsies of Patients with HIGH-RISK Neuroblastoma Disclose Exosomal miRNA Modulation after the Induction Therapy
Morini, M; (...); Varesio, L
Meeting Abstract. 2017
Liquid Biopsies Provide Exosomal MicroRNAs as Biomarkers of the Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients
Morini, M; (...); Varesio, L
Meeting Abstract. 2018
Liquid Biopsy Micro-RNA Profiling in Meduloblastoma
Yanez, Y; (...); Canete, A
Meeting Abstract. 2018
Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.
Trinidad EM; (...); Font de Mora J
Article. 10.1093/bib/bbac575. 2023
Long-Term Results for Infants with Neuroblastoma Treated Between 2000 and 2D004 According to INES Protocols -INESFU- A SIOPEN Study
Munzer, C; (...); Gambart, M
Meeting Abstract. 2019
Lymph microvascularization as a prognostic indicator in neuroblastoma.
Tadeo I; (...); Noguera R
Article. 10.18632/oncotarget.25457. 2018
Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care
de Rojas, T; (...); Moreno, L
Article. 10.1007/s11060-017-2713-4. 2018
Methodological advances in the discovery of novel neuroblastoma therapeutics.
Segura MF; (...); Moreno L
Article. 10.1080/17460441.2022.2002297. 2022
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs.
Reinal, Ignacio; (...); Sepulveda, Pilar
Article. 10.3390/antiox12071378. 2023
Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study.
Carceller, F; (...); Moreno, L
Meeting Abstract. 2019
MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging
Fernández Patón M; (...); Martí-Bonmatí L
Article. 10.1007/s10278-021-00512-8. 2021
MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; (...); Jaspan T
Article. 10.1148/radiol.211464. 2022
MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
Olivera, GG; (...); Herrero, MJ
Article. 10.3390/ijms21082714. 2020
Nefroblastoma. Experiencia a largo plazo en el abordaje multidisciplinario.
Rodriguez Iglesias P; (...); Boronat Tormo F
Abstract of Published Item. 2018
Neonatal Suprarenal Masses: An Observational Approach
Papadakis, V; (...); Canete, A
Meeting Abstract. 2018
Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers.
Cañete A; (...); Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG)
Article. 10.1016/j.canep.2022.102145. 2022
Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas
Ribelles, AJ; (...); Canete, A
Article. 10.3390/jpm11040268. 2021
Optimising Urinary Catecholamine Diagnostics for Neuroblastoma Patients
Matser, Y; (...); Tytgat, G
Meeting Abstract. 2020
OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
Nobre, L; (...); Tabori, U
Meeting Abstract. 2020
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
Nobre L; (...); Tabori U
Article. 10.1200/PO.19.00298. 2020
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Vo, Kieuhoa T.; (...); Matthay, Katherine K.
Article. 10.1002/pbc.29616. 2022
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy.
Urtasun, Andrea; (...); Herrero, Maria Jose
Article. 10.3390/cancers15051424. 2023
PHARMACOGENETIC VARIANTS ASSOCIATED WITH TREATMENT RESPONSE IN NEUROBLASTOMA
Olivera, G; (...); Alino, SF
Meeting Abstract. 2018
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
Olivera, Gladys; (...); Alino, Salvador F.
Review. 10.20517/cdr.2018.25. 2019
Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
Olivera, GG; (...); Herrero, MJ
Review. 10.3390/ijms22189815. 2021
Phase 1 Combination Dose-Finding/Phase 2 Expansion Cohorts of Lenvatinib plus Etoposide plus Ifosfamide in Patients Aged 2 to <= 25 Years with Relapsed/Refractory Osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2019
Phase 1 Study of Regorafenib in Combination With Vincristine and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Casanova, M; (...); Geoerger, B
Meeting Abstract. 2020
Phase I combination dose-finding/phase II expansion cohorts of lenvatinib plus etoposide plus ifosfamide in patients (pts) aged 2 to <= 25 years with relapsed/refractory (r/r) osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2019
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
Casanova, Michela; (...); Geoerger, Birgit
Meeting Abstract. 2020
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050) ? .
Gaspar N; (...); Casanova M
Article. 10.1016/j.esmoop.2021.100250. 2021
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma
Grill, J; (...); Vassal, G
Article. 10.1200/JCO.2017.76.0611. 2018
Plasma Metabolomic Profiling Differentiates High- and Low-Risk Neuroblastoma Patients
Quintas, G; (...); Segura, V
Meeting Abstract. 2018
Precision medicine in Ewing sarcoma: a translational point of view.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-020-02298-7. 2020
PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers.
Martí-Bonmatí L; (...); Neri E
Article. 10.1186/s41747-020-00150-9. 2020
Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study
Carceller, Fernando; (...); Moreno, Lucas
Meeting Abstract. 2023
Progressively transformed germinal center (PTGC): a challenging diagnosis. Four new pediatric cases
Andres, MM; (...); Fernandez, JM
Meeting Abstract. 2018
Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
Juan Ribelles A; (...); Castel V
Correction. 10.1038/s41598-020-58428-2. 2020
Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
Rodriguez Gutierrez D; (...); Jaspan T
Article. 10.1158/1078-0432.CCR-19-3154. 2020
Radiotherapy quality assurance in paediatric clinical trials: first report from six QUARTET-affiliated trials.
Kelly, Sarah M.; (...); Mandeville, Henry
Article. 10.1016/j.radonc.2023.109549. 2023
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
Lassaletta, Alvaro; (...); Juan-Ribelles, Antonio
Meeting Abstract. 2023
Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study.
Casanova M; (...); Geoerger B
Article. 10.1158/1078-0432.CCR-23-0257. 2023
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1148/ryai.230208. 2024
Response rate in cardiac resynchronization therapy patients implanted with a left ventricular quadripolar lead and the MultiPoint(TM) Pacing feature activated. QUARTO III.
Osca, Joaquin; (...); Alzueta, Javier
Article. 10.1111/eci.13935. 2022
Results of a survey on the treatment of adolescents and young adult (AYA) sarcoma patients in Spain at present time.
Mata Fernandez, Cristina; (...); Morales CV
Article. 10.1007/s12094-022-02912-w. 2022
Retinoblastoma and mosaic 13q deletion: a case report
Gargallo P; (...); Canete, A
Article. 10.1186/s40942-021-00321-9. 2021
Retinoblastoma: towards an earlier diagnosis.
Gargallo P; (...); Cañete A
Article. 10.1016/j.oftal.2018.05.003. 2018
Review: Ewing Sarcoma Predisposition.
Gargallo P; (...); Cañete A
Article. 10.1007/s12253-019-00765-3. 2019
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Morgenstern, DA; (...); Ladenstein, R
Article. 10.1002/pbc.27363. 2018
Safety and PK (pharmacokinetic) profile of niraparib (nir) plus dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study
Doz, Francois; (...); Rubio-San-Simon, Alba
Meeting Abstract. 2023
Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN plus etoposide (ETP) plus ifosfamide (IFM) in patients (pts) aged 2 to <= 25 years with relapsed/refractory osteosarcoma (OS).
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.11527. 2018
Single-Agent Expansion Cohort of Lenvatinib and Combination Dose-Finding Cohort of Lenvatinib plus Etoposide plus Ifosfamide in Patients Aged 2 to <= 25 Years with Relapsed/Refractory Osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2018
Spinal cord compression syndrome in pediatric oncology: review of a series of cases in a tertiary level center.
Sánchez HM, Guill JB, Zúñiga RV
Case Reports. 10.1016/j.anpede.2024.01.008. 2024
Spinal cord compression syndrome in pediatric oncology: Review of a series of cases in a tertiary level center
Sanchez, Helena Martinez, Guill, Julia Balaguer, Zuniga, Roberto Velasco
Letter. 10.1016/j.anpedi.2023.09.013. 2024
Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study.
Gatta G; (...); JARC Pilot Study Toronto Guidelines Working Group
Article. 10.1002/pbc.29020. 2021
Success of the HR-NBL/SIOPEN local control trial strategy in high risk neuroblastoma patients undergoing high dose therapy with peripheral stem cell transplantation
Ladenstein, R; (...); Botterberg, T
Meeting Abstract. 2018
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.
Tena, I; (...); Pacak, K
Article. 10.1177/1179554918763367. 2018
Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results
Papadakis, Vassilios; (...); Canete, Adela
Article. 10.3390/cancers14164007. 2022
Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project
Juan Ribelles A; (...); Ladenstein, R
Article. 10.1007/s12094-017-1820-1. 2018
Survival and Health Care Burden of Children With Retinoblastoma in Europe.
Virgili G; (...); Gatta G
Article. 10.1001/jamaophthalmol.2024.4140. 2024
THE BENCHISTA PROJECT: INTERNATIONAL BENCHMARKING OF CHILDHOOD CANCER SURVIVAL BY TUMOUR STAGE
Cortes, Angela Lopez; (...); Pritchard-Jones, Kathy
Article. 2022
The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries
Alia, Donjeta B.; (...); Nyaywa, Mutale
Article. 10.1016/S2214-109X(22)00250-9. 2022
The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Rubio-San-Simon, A.; (...); Moreno, L.
Article. 10.1007/s12094-021-02649-y. 2021
TIAM1 variants improve clinical outcome in neuroblastoma
Sanmartin, E; (...); Font de Mora J
Article. 10.18632/oncotarget.16787. 2017
Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries.
Fabian, Ido Didi; (...); Bowman, Richard
Article. 10.1136/bjophthalmol-2020-316613. 2020
Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
Burgos-Panadero, R; (...); Noguera, R
Article. 10.1016/j.ijpharm.2021.121058. 2021
Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma
Burgos-Panadero, R; (...); Noguera, R
Article. 10.1186/s12885-019-5693-2. 2019
Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?
Lopez-Carrasco, Amparo; (...); Noguera, Rosa
Article. 10.3390/ijms25168733. 2024